Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study

PURPOSE: Treatment options are limited after the failure of first-and second-line treatments in patients with HER2(+) metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Huo, Haoran, Nie, Yanan, Xue, Jiadong, Yuan, Zengjiang, Zhang, Zhenyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633934/
https://www.ncbi.nlm.nih.gov/pubmed/36316114
http://dx.doi.org/10.5230/jgc.2022.22.e33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633934/
https://www.ncbi.nlm.nih.gov/pubmed/36316114
http://dx.doi.org/10.5230/jgc.2022.22.e33

Ejemplares similares